Suchergebnisse - "YO603Y8113"

PubPharm (127)

1

Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Podzamczer, D. | Imaz, A. | Lopez-Lirola, A. | +25

2

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Mandelbrot, L. | Tubiana, R. | Frange, P. | +114

3

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

enthalten in: Viruses | 2023

von Fabbiani, M. | Masini, M. | Rossetti, B. | +13

4

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older : a PK substudy of the SMILE trial

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Abdalla, S. | Compagnucci, A. | Zheng, Y. | +39

5

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

enthalten in: Viruses | 2023

von Salvo, P. | Farinacci, D. | Ciccullo, A. | +11

6

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection : the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Chéret, A. | Bauer, R. | Meiffrédy, V. | +12

7

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

8

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI) : A multicenter observational study

enthalten in: PloS one | 2022

von Elmekaty, E. | Alibrahim, R. | Hassanin, R. | +8

9

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

enthalten in: HIV research & clinical practice | 2021

von Monin, M. | Kümmerle, T. | Schneider, J. | +16

10

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV

enthalten in: AIDS (London, England) | 2021

von Momper, J. | Wang, J. | Stek, A. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]